Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?

By Remme Willem   Deckers Jaap   Fox Kim   Ferrari Roberto   Bertrand Michel   Simoons Maarten  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 161-170

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit

By Brugts Jasper J   Boersma Eric   Simoons Maarten L  

Pharmacogenomics, Vol. 11, Iss. 8, 2010-08 ,pp. : 1115-1126

Future Medicine

Access to resources Recommend Favorite

Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 10, Iss. 2, 2010-06 ,pp. : 91-96

Bentham Science Publishers

Access to resources Recommend Favorite

Angiotensin-Converting Enzyme Inhibition Influences Serum Levels of Advanced Glycation End Products in Patients with Coronary Artery Disease: Results from a HOPE Substudy

By  

Heart Drug, Vol. 3, Iss. 2, 2003-08 ,pp. : 67-72

Karger

Access to resources Recommend Favorite